Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor - Wikidata - wikimedia - TriplyDB

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

http://www.wikidata.org/entity/Q28292154

about

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH The PCSK9 decade New developments in atherosclerosis: clinical potential of PCSK9 inhibition Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9 Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Low density lipoprotein receptor class A repeats are O-glycosylated in linker regions Cholesterol, the central lipid of mammalian cells Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)Increased cholesterol content in gammadelta (γδ) T lymphocytes differentially regulates their activation.PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR.Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice.Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII.PCSK9: a convertase that coordinates LDL catabolism.A new method for measurement of total plasma PCSK9: clinical applications.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.PCSK9 targets important for lipid metabolism Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.PCSK9: an emerging target for treatment of hypercholesterolemia.Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.

P2860

726ba851b96ada02e8b245b6f2e7c242acd3d7a6

P248

Q21136366-D3CE8CD1-BF6C-451A-A1C1-150BB070B5B7 Q24294486-E6CC1AFF-E362-4F64-B371-FCBE0D80F910 Q24297165-E15F27EC-62F7-4A67-BFEF-54E8EDAAF262 Q24615397-A9E7A8E7-AAE5-476E-9393-E89A2E5F160A Q26783407-A42A70E4-AEB9-4EC5-B629-BC5064982A49 Q26786549-9D510BD8-A087-4880-BBF6-F8CC99D26731 Q27003094-CC7EBDD4-7B93-4B54-8104-678AC0B64827 Q27009477-6304518C-19D4-45D1-BA50-6FAC02175C87 Q27026250-61E0F714-E676-4FAB-9431-10EF9D8505BB Q27339783-4D6E7E9E-FE3D-4C26-9CB1-CF5B60CF462A Q27655476-1C6FAAB5-BFAD-450A-B1F7-CD5BA7FEEC5A Q27665195-02465B64-293D-4007-BBAF-1D96A68B4A47 Q30541820-2374DB41-2823-4B02-8CD1-0EB6D19438D7 Q33532964-89D16C91-0AD4-4EE8-AF91-8B26B7177D63 Q33599961-2C2327B4-B111-405C-BC5D-1A1964FFE7AA Q33792840-5E6C5FD5-1990-4E95-BCF8-3FE6E1B8E7D0 Q34021021-7E269819-8470-4291-A7B8-6DDAA508AAA4 Q34227474-19E0B2DE-70CF-4E30-9CF8-C986E29B42F0 Q34433146-84AE50D6-E6D5-4503-BBF1-E551228F8113 Q34479132-85C8C53F-D0C2-4BE5-9114-9AF3C07A6F60 Q34568486-9A1C854D-515A-4BA6-A79B-716AE4ACF2BB Q34723257-3FECB161-1180-4C6F-951E-459814661438 Q34737657-4FDBA590-28EF-49B2-98D9-71F3AFD6363D Q35262593-F9A53A90-5163-47A9-BD8D-2DCF7FF68F0C Q35767551-B3A12595-375C-42B1-9529-8C51D8A6C5B4 Q35879455-CA412148-0199-4DE7-BE0F-7B6F783D5BC8 Q35883857-C27F9933-CE58-40A9-9DC1-3F54C1EC20C6 Q36145238-B1101395-1975-48F8-9292-D4A9AD9CB1DF Q36281706-4996CB98-6B98-464C-ACDA-1D478771A8AE Q36520347-BC98C373-1EBA-448B-9C5B-3F2A0E2B916F Q36520700-953B032F-86DA-4D8F-931D-ACA41E17A827 Q36925157-88256906-6615-4F94-AF32-FE310AB21A97 Q37048482-AB7BE770-55CE-48F3-AC5D-8D7EA3AE0724 Q37173223-141ABA99-AC71-477E-ABAC-9EFC41BAEED5 Q37463260-E0F91487-ED5B-4998-A011-24D7E4859063 Q37688760-37FC18CA-50B0-4FBA-B0C7-5A5A6516409B Q37703261-2FE298DD-817F-4B5F-8626-1AF0A11FCDF7 Q37789741-E8BAAB57-2AE9-49C8-95F4-E027AE64D28E Q37825903-C65BB031-BD14-470F-BA40-99ABAF8CA3F2 Q38001736-9C0EBE7C-A02D-4841-BF11-2F0208590D3E

P2860

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

http://www.wikidata.org/entity/Q28292154

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Structural requirements for PC ...... w-density lipoprotein receptor

@ast

Structural requirements for PC ...... w-density lipoprotein receptor

@en

Structural requirements for PC ...... w-density lipoprotein receptor

@nl

type

label

Structural requirements for PC ...... w-density lipoprotein receptor

@ast

Structural requirements for PC ...... w-density lipoprotein receptor

@en

Structural requirements for PC ...... w-density lipoprotein receptor

@nl

prefLabel

Structural requirements for PC ...... w-density lipoprotein receptor

@ast

Structural requirements for PC ...... w-density lipoprotein receptor

@en

Structural requirements for PC ...... w-density lipoprotein receptor

@nl

P1433

Q28292154-6440FD01-1B23-43E4-8B6C-98916CC227DC

P1476

Q28292154-F6A6D39D-8B08-489C-844F-B8E408B94F62

P2093

Q28292154-4ECDE1B9-4A3D-4B95-B623-C01EEAF80E84

Q28292154-9D722E0D-9DFA-4476-A988-68FF80A2456A

Q28292154-B3F44816-E637-4354-9F7A-2B73167BCFE6

Q28292154-E427EACC-1289-4B70-AEBB-3442D6EACBE9

Q28292154-ECF49722-6980-4515-92D2-3DEAF716FEAA

P2860

Q28292154-0103360A-5543-4923-9379-6D5AFF4F365F

Q28292154-0C810BB3-9921-458B-AFD7-1FF23471E3D5

Q28292154-0D51A18B-2C38-4043-8170-11D1EFE8209E

Q28292154-10DA1758-E392-4143-B1D0-8228A70DD0D2

Q28292154-167E6AD8-7C0E-4746-B87B-186BEC45A1AE

Q28292154-39A2F9E1-A382-4959-85E2-4F32920D4772

Q28292154-41070A3B-0C49-4F8E-9E3B-B77854A5C03C

Q28292154-5530CB26-BDD4-4EDC-8FA2-56902031E811

Q28292154-6D4BD7EC-95DE-443D-AD35-901C3B962DBE

Q28292154-70D4DA2A-A3CA-4B00-843A-BB760F559270

P304

Q28292154-B5946E72-BDAD-4327-82A9-3EC7876D9079

P31

Q28292154-C6E3D231-2B36-42E1-B06B-E2ED642C87CA

P3181

Q28292154-E49D479A-3B91-4562-AAF4-1E306C82EE57

P356

Q28292154-0BE1667B-D09C-4975-8F9C-8B39287056BF

P407

Q28292154-52B74E64-7323-4047-8EB6-46BEF3C85086

P433

Q28292154-FE265767-18C5-442B-8A14-62F1C63168A1

P478

Q28292154-73F53D91-1527-4133-AE79-258E9683371F

P577

Q28292154-A1CCD9A5-518A-4E9C-A541-9B705EEEC030

P5875

Q28292154-633A51CB-054B-4083-A0A0-4E7B5B978D8F

P698

Q28292154-9C3161EB-D2A3-47A2-8E2B-24EFBF174D44

P921

Q28292154-A6B9F6ED-23DE-4866-A540-639EEE86BE5B

P932

Q28292154-1C2ADE66-1909-4B3F-9CEC-320CBA0E75CB

P3181

P356

PNAS.0806312105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Structural requirements for PC ...... w-density lipoprotein receptor

@en

P2093

Da-Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Helen H Hobbs

http://www.w3.org/2001/XMLSchema#string

Jonathan C Cohen

http://www.w3.org/2001/XMLSchema#string

Rita Garuti

http://www.w3.org/2001/XMLSchema#string

Wan-Jin Tang

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Functional characterization of Narc 1, a novel proteinase related to proteinase K

The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA

Domain map of the LDL receptor: sequence homology with the epidermal growth factor precursor

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

The LDL receptor gene: a mosaic of exons shared with different proteins

Molecular biology of PCSK9: its role in LDL metabolism

P304

13045-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

913442

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0806312105

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23220097

http://www.w3.org/2001/XMLSchema#string

P698

18753623

http://www.w3.org/2001/XMLSchema#string

P921

P932

2526098

http://www.w3.org/2001/XMLSchema#string